Cargando…
Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model
Background: With the advent of aging society of China, fundus diseases related to pathological neovascularization, including age-related macular degeneration (AMD), diabetic macular edema (DME), and pathological myopia (PM), have become an increasingly serious medical and health problems. As effecti...
Autores principales: | Cui, Zhuang, Zhou, Wei, Chang, Qinxue, Zhang, Tiantian, Wang, Hui, Meng, Xiangda, Liu, Yuanyuan, Yan, Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8676057/ https://www.ncbi.nlm.nih.gov/pubmed/34926500 http://dx.doi.org/10.3389/fmed.2021.750132 |
Ejemplares similares
-
Switching to Conbercept in Diabetic Macular Edema After Unsatisfactory Response to Previous Intravitreal Injection of Ranibizumab
por: Xing, Peiyu, et al.
Publicado: (2023) -
Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis
por: Zhou, Pengxiang, et al.
Publicado: (2021) -
Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis
por: Wang, Luping, et al.
Publicado: (2018) -
Comparison of the Efficacy and Safety of Intravitreal Conbercept with Intravitreal Ranibizumab for Treatment of Diabetic Macular Edema: A Meta-Analysis
por: Sun, Xiaolei, et al.
Publicado: (2020) -
The efficacy and safety of aflibercept and conbercept in diabetic macular edema
por: Cai, Siwei, et al.
Publicado: (2018)